Evidence map›Paper›PMID 28919897›Full record

ArticleFrontiers in immunology2017

Altered Immune Activation and IL-23 Signaling in Response to

Øyvind Bruserud, Eirik Bratland, Alexander Hellesen, Nicolas Delaleu, Håkon Reikvam, Bergithe E Oftedal, Anette S B Wolff

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Long-term follow-up of autoimmune polyendocrine syndrome type 1 in Norway.The Journal of clinical endocrinology and metabolism · 2026
    Article
  3. A novel heterozygous pathogenicJournal of human immunity · 2025
    Article
  4. Article
  5. The emerging family of RORγtNature reviews. Immunology · 2024
    Review
  6. Article
  7. Article
  8. The Role of AIRE in the Immunity AgainstFrontiers in immunology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Øyvind BruserudDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Eirik BratlandDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Alexander HellesenDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Nicolas DelaleuBroegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.
Håkon ReikvamDepartment of Medicine, Haukeland University Hospital, Bergen, Norway.
Bergithe E OftedalDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Anette S B WolffDepartment of Clinical Science, University of Bergen, Bergen, Norway.
University of Bergen · NOHaukeland University Hospital · NOSIB Swiss Institute of Bioinformatics · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAutoimmune polyendocrine syndrome type 1 (APS-1) is a rare, childhood onset disease caused by mutations in the

methodsWhole blood was stimulated with

resultsWe found an altered immune response in APS-1 patients compared with healthy controls. Patients fail to increase the essential ILs, such as IL-2, IL-17A, IL-22, and IL-23, when stimulating whole blood with

conclusionAPS-1 patients have an altered immune response to

Indexed as

autoimmune polyendocrine syndrome type 1chronic mucocutaneous candidiasisIL-17IL-22IL-23monocytes

Identifiers

PMID28919897
PMCPMC5585148
OpenAlexW2751573909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.